Barclays analyst Luke Sergott lowered the firm’s price target on PerkinElmer to $140 from $145 and keeps an Equal Weight rating on the shares. The analyst says 2023 will likely be a "tale of 2 cities" for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PKI:
- PerkinElmer CEO Prahlad Singh appointed to Amphenol board
- PerkinElmer to meet or exceed Q4 guidance
- PerkinElmer target raised to $150, added to ‘TAP Outperform’ list at Evercore
- PerkinElmer upgraded to Overweight from Sector Weight at KeyBanc
- Early notable gainers among liquid option names on December 12th